Last Updated:

Q3 '20


quotes and stock data delayed 15 minutes



Burn Rate (Qtr)


Company Profile

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

NanoFlu vaccine


BLA: Preparing Submission



COVID-19 Vaccine

Phase 3 Initiation (US Trial)

December 2020

RSV Vaccine

RSV - Infants Via Maternal Immunization

Phase 3 Topline Data/ FDA Recommends Additional Studies


RSV Vaccine

RSV - Older Adults

Phase 2

Matrix-M (with Serum Institute of India)

Malaria Vaccine

Phase 2b (Top-line Data)

H2 2020

RSV Vaccine

RSV - Pediatrics

Phase 1

Recent Posts

See what the community is saying - click to see full post

NVAX - Novavax Announces COVID-19 Vaccine Clinical Development Progress

NVAX- Novavax COVID-19 Vaccine Update

NVAX - Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020 (10/19 - 10/21)

MRNA - Announces Publication in NEJM of Interim Results From Older Adult Age Cohorts in Phase 1 Study mRNA-127

NVAX - Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom

NVAX - Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medi

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon